Biddeford-based startup Prapela Inc. is seeking regulatory OK for use of a technology-enabled bassinet pad as a complementary treatment for newborns in opioid withdrawal.
Clearance by U.S. Food and Drug Administration would make Prapela’s product the first such device to treat newborns diagnosed with neonatal opioid withdrawal syndrome, the company said. Read more
The Bar Harbor Planning Board has approved a plan by the Jackson Laboratory to build a 20,000-square-foot expansion to its Rare Disease Translational...
Researchers at Bigelow Laboratory for Ocean Sciences believe algae can make a big splash in the agricultural, aquaculture and pharmaceutical industries,...
The University of Maine System said this week it will work with a national consultant to study the feasibility of launching the state’s...